Polymeric Nanoparticles for Drug Delivery

  • Juliana M. Chan
  • Pedro M. Valencia
  • Liangfang Zhang
  • Robert Langer
  • Omid C. Farokhzad
Part of the Methods in Molecular Biology book series (MIMB, volume 624)

Abstract

The use of biodegradable polymeric nanoparticles (NPs) for controlled drug delivery has shown significant therapeutic potential. Concurrently, targeted delivery technologies are becoming increasingly important as a scientific area of investigation. In cancer, targeted polymeric NPs can be used to deliver chemotherapies to tumor cells with greater efficacy and reduced cytotoxicity on peripheral healthy tissues. In this chapter, we describe the methods of (1) preparation and characterization of drug-encapsulated polymeric NPs formulated with biocompatible and biodegradable poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) (PLGA-b-PEG) copolymers; (2) surface functionalization of the polymeric NPs with the A10 2'-fluoropyrimidine ribonucleic acid (RNA) aptamers that recognize the prostate-specific membrane antigen (PSMA) on prostate cancer cells; and (3) evaluation of the binding properties of these targeted polymeric NPs to PSMA-expressing prostate cancer cells in vitro and in vivo. These methods may contribute to the development of other useful polymeric NPs to deliver a spectrum of chemotherapeutic, diagnostic, and imaging agents for various applications.

Key words

Polymeric nanoparticles polymer conjugation chemistry targeted drug delivery surface functionalization aptamers chemotherapy microfluidics 

References

  1. 1.
    Farokhzad, O. C., Cheng, J., Teply, B. A., et al. (2006) Targeted nanoparticle–aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103, 6315–6320.CrossRefPubMedGoogle Scholar
  2. 2.
    Avgoustakis, K. (2004) Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr Drug Deliv 1, 321–333.CrossRefPubMedGoogle Scholar
  3. 3.
    Gref, R., Domb, A., Quellec, P., et al. (1995) The controlled intravenous delivery of drugs using peg-coated sterically stabilized nanospheres. Adv Drug Deliver Rev 16, 215–233.CrossRefGoogle Scholar
  4. 4.
    Fessi, H., Puisieux, F., Devissaguet, J. P., Ammoury, N., and Benita, S. (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55, R1–R4.CrossRefGoogle Scholar
  5. 5.
    Allemann, E., Gurny, R., and Doelker, E. (1992) Preparation of aqueous polymeric nanodispersions by a reversible salting-out process – influence of process parameters on particle-size. Int J Pharm 87, 247–253.CrossRefGoogle Scholar
  6. 6.
    DeMello, J. and DeMello, A. (2004) Microscale reactors: nanoscale products. Lab Chip 4, 11n–15n.CrossRefPubMedGoogle Scholar
  7. 7.
    Karnik, R., Gu, F., Basto, P., et al. (2008) Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett 8, 2906–2912.CrossRefPubMedGoogle Scholar
  8. 8.
    Cheng, J., Teply, B. A., Sherifi, I., et al. (2007) Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28, 869–876.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Juliana M. Chan
    • 1
  • Pedro M. Valencia
    • 2
  • Liangfang Zhang
    • 3
  • Robert Langer
    • 2
  • Omid C. Farokhzad
    • 4
  1. 1.Department of BiologyMassachusetts Institute of TechnologyCambridgeUSA
  2. 2.Department of Chemical Engineering and Division of Health Science and TechnologyMassachusetts Institute of TechnologyCambridgeUSA
  3. 3.Department of NanoEngineeringUniversity of California-San DiegoLa JollaUSA
  4. 4.Laboratory of Nanomedicine and Biomaterials, Department of AnesthesiologyBrigham Women’s Hospital, Harvard Medical SchoolBostonUSA

Personalised recommendations